CAR-T
Gilead’s CAR-T therapy Yescarta rejected for NHS use in Scotland
February 12, 2019Manufacturing and Production, Sales and Marketing CAR-T, Cancer, Gilead, NHS, Scotland, Yescarta, kite pharma
It’s bad news for Scottish patients living with aggressive forms of non-Hodgkin lymphoma (NHL) as it emerges that the Scottish …
Novartis’ CAR-T therapy Kymriah gets NICE green light in diffuse large B-cell lymphoma
February 1, 2019Medical Communications, Sales and Marketing CAR-T, Cancer, Kymriah, NICE, Novartis, lymphoma, pharma
NICE has announced another momentous decision for lymphoma patients in England and Wales:, recommending Novartis’ chimeric antigen receptor T cell …
Canada Health approves Novartis’ CAR-T therapy Kymriah
January 18, 2019Medical Communications CAR T, CAR-T, Canada, Cancer, Kymriah, Novartis, oncology
Health Canada has approved Novartis’ CAR-T therapy Kymriah for use in paediatric and young adult patients aged between three and …
Takeda unveils three new discovery and development collaborations in immuno-oncology
January 4, 2019Medical Communications, Research and Development CAR-T, Crescendo Biologics, Memorial Sloan Kettering Cancer Center, Noile-Immune, Takeda, pharma
Takeda has revealed that it is set to bolster its novel immuno-oncology portfolio with three new research collaborations. The Japanese …
Merck KGaA hands over CAR-T therapy business to Intrexon in deal worth $175 million
December 20, 2018Business Services, Medical Communications, Sales and Marketing CAR T, CAR-T, Cancer, Germany, Intrexon, Merck KGaA, darmstadt, oncology
German pharma firm Merck KGaA has agreed to hand over its CAR-T therapy business to US company Intrexon in a …
Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma
December 3, 2018Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma
Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …
Kymriah to be made available in UK for paediatric leukaemia patients via Cancer Drugs Fund
November 15, 2018Sales and Marketing CAR-T, Cancer, Cancer Drugs Fund, Kymriah, NHS, NICE, leukaemia, pharma
NICE has announced its recommendation that Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) be made available in the treatment of relapsed …
20 year old man died after leukaemia cell was accidently mixed into CAR T therapy
October 2, 2018Manufacturing and Production CAR T, CAR-T, Cancer, Kymriah, Novartis, leukaemia, oncology
A 20 year old man died after a single leukaemia cell accidentally ended up in a batch of cells that …
Novartis strike $40m deal with Chinese firm Cellular Biomedicine
September 28, 2018Medical Communications CAR T, CAR-T, China, Kymriah, Novartis, cellular biomedicine, prc
Swiss multinational Novartis have paired up with Chinese drugmaker Cellular Biomedicine (CBMG) in order to manufacture CAR-T therapy Kymriah in …
NICE decision could limit future development of CAR T therapies; Evelyn Warner comments on NICE’s decision making process
September 25, 2018Research and Development CAR T, CAR-T, Cancer, Duff and Phelps, Kymriah, access, oncology, pricing
Lack of access to CAR T therapies in the United Kingdom could hinder the development of effective personalised cancer treatments, …
NICE rejects CAR-T therapy Kymriah for DLBCL in adults
September 19, 2018Research and Development CAR T, CAR-T, Kymriah, NICE, Novartis, leukaemia
The National Institute for health and Care Excellence (NICE) has rejected Novartis’ CAR-T therapy Kymriah for use in adults with …
Novartis’ CAR T therapy Kymriah to become available on the NHS
September 5, 2018Research and Development CAR T, CAR-T, Gilead, Kymriah, NHS, Novartis
Novartis’ Kymriah is set to become the first CAR T therapy to become available on the NHS after it was …
Novartis to create 450 new jobs at Aargau site after Kymriah thumbs up
August 29, 2018Research and Development CAR T, CAR-T, Jobs, Kymriah, Novartis
Swiss multinational Novartis is set to create up to 450 new jobs following the investment of 90 million Swiss Francs …
Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies
August 28, 2018Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma
Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …
CHMP recommends Novartis’ CAR-T therapy Kymriah for EU approval
July 5, 2018Sales and Marketing CAR-T, CHMP, EMA, EU, Kymriah, Novartis, pharma
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Medicines Agency (EMA) approve Novartis’ CAR-T …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
